Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells

Oncogene volume 23, pages 3024–3032 (2004)Cite this article

Abstract

Previously, bone morphogenetic protein (BMP)-2 and -4 have been shown to inhibit proliferation and induce apoptosis in human myeloma cells. BMP-2 and -4 belong to a subgroup of BMPs using the BMP receptors Alk-3 or -6. In this study, we examined the effects on human myeloma cells of BMP-6 and -7, members of a different BMP subgroup, which mainly utilize Alk-2 as their receptor. All cell lines examined expressed mRNA for the BMP-6 and -7 receptor Alk-2. We did not detect transcripts for the BMP-2 and -4 receptors Alk-3 or Alk-6 in INA-6 and RPMI-8226 cells by RT–PCR. Accordingly, the intracellular signalling molecules Smad-1, -5 and -8 were not phosphorylated by BMP-4 in INA-6 and RPMI-8226 cells. The expression patterns of various BMP receptors in the myeloma cell lines explained the differences in responses to the various BMPs. Alk-2-expressing cell lines responded with growth inhibition and apoptosis to BMP-6 and -7, whereas cell lines lacking both Alk-3 and -6 were resistant to BMP-4. Soluble Alk-3 and -6 were able to neutralize the BMP-4 effects in BMP-4-responsive cell lines. All BMPs reduced viability in more than 70% of purified primary myeloma cell samples. BMPs have intriguing antitumor effects in vitro. Importantly, myeloma cells not responsive to BMP-2 and -4 may still be sensitive to BMP-6 or -7. It is possible that therapeutic use of BMP or BMP analogues could have an impact on both myeloma bone disease and myeloma cell growth.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Beck HN, Drahushuk K, Jacoby DB, Higgins D and Lein PJ . (2001). BMC Neurosci., 2, 12.

  • Bhatia M, Bonnet D, Wu D, Murdoch B, Wrana J, Gallacher L and Dick JE . (1999). J. Exp. Med., 189, 1139–1148.

  • Borset M, Hjorth-Hansen H, Seidel C, Sundan A and Waage A . (1996). Blood, 88, 3998–4004.

  • Borset M, Waage A, Brekke OL and Helseth E . (1994). Eur. J. Haematol., 53, 31–37.

  • Brenne AT, Ro TB, Waage A, Sundan A, Borset M and Hjorth-Hansen H . (2002). Blood, 99, 3756–3762.

  • Chang CF, Lin SZ, Chiang YH, Morales M, Chou J, Lein P, Chen HL, Hoffer BJ and Wang Y . (2003). Stroke, 34, 558–564.

  • Durie BG and Salmon SE . (1975). Cancer, 36, 842–854.

  • Ebisawa T, Tada K, Kitajima I, Tojo K, Sampath TK, Kawabata M, Miyazono K and Imamura T . (1999). J. Cell Sci., 112 (Part 20), 3519–3527.

  • Franzen A and Heldin NE . (2001). Biochem. Biophys. Res. Commun., 285, 773–781.

  • Friedlaender GE, Perry CR, Cole JD, Cook SD, Cierny G, Muschler GF, Zych GA, Calhoun JH, LaForte AJ and Yin S . (2001). J. Bone Joint Surg. Am., 83-A (Suppl 1), S151–S158.

  • Gazitt Y . (1999). Leukemia, 13, 1817–1824.

  • Gilboa L, Nohe A, Geissendorfer T, Sebald W, Henis YI and Knaus P . (2000). Mol. Biol. Cell, 11, 1023–1035.

  • Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH and Kern SE . (1996). Science, 271, 350–353.

  • Hallahan AR, Pritchard JI, Chandraratna RAS, Ellenbogen RG, Geyer JR, Overland RP, Strand AD, Tapscott SJ and Olson JM . (2003). Nat. Med., 9, 1033–1038.

  • Hjertner O, Hjorth-Hansen H, Borset M, Seidel C, Waage A and Sundan A . (2001). Blood, 97, 516–522.

  • Jackson N, Lowe J, Ball J, Bromidge E, Ling NR, Larkins S, Griffith MJ and Franklin IM . (1989). Clin. Exp. Immunol., 75, 93–99.

  • Jernberg-Wiklund H, Pettersson M and Nilsson K . (1991). Eur. J. Haematol., 46, 231–239.

  • Kawamura C, Kizaki M, Yamato K, Uchida H, Fukuchi Y, Hattori Y, Koseki T, Nishihara T and Ikeda Y . (2000). Blood, 96, 2005–2011.

  • Kim IY, Lee DH, Ahn HJ, Tokunaga H, Song W, Devereaux LM, Jin D, Sampath TK and Morton RA . (2000). Cancer Res., 60, 2840–2844.

  • Nishihara T, Okahashi N and Ueda N . (1993). Biochem. Biophys. Res. Commun., 197, 985–991.

  • Nohe A, Hassel S, Ehrlich M, Neubauer F, Sebald W, Henis YI and Knaus P . (2002). J. Biol. Chem., 277, 5330–5338.

  • Paine-Saunders S, Viviano BL, Economides AN and Saunders S . (2002). J. Biol. Chem., 277, 2089–2096.

  • Rodriguez-Leon J, Merino R, Macias D, Ganan Y, Santesteban E and Hurle JM . (1999). Nat. Cell Biol., 1, 125–126.

  • Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IM, Abildgaard N, Waage A and Borset M . (2000). Blood, 95, 388–392.

  • Shima Y, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K and Kishimoto T . (1995). Blood, 85, 757–764.

  • Tarte K, Zhan F, De Vos J, Klein B and Shaughnessy J . (2003). Blood, 102, 592–600.

  • ten Dijke P, Yamashita H, Ichijo H, Franzen P, Laiho M, Miyazono K and Heldin CH . (1994a). Science, 264, 101–104.

  • ten Dijke P, Yamashita H, Sampath TK, Reddi AH, Estevez M, Riddle DL, Ichijo H, Heldin CH and Miyazono K . (1994b). J. Biol. Chem., 269, 16985–16988.

  • Tsuchida K, Sawchenko PE, Nishikawa S and Vale WW . (1996). Mol. Cell Neurosci., 7, 467–478.

  • Urashima M, Ogata A, Chauhan D, Hatziyanni M, Vidriales MB, Dedera DA, Schlossman RL and Anderson KC . (1996). Blood, 87, 1928–1938.

  • Urist MR . (1965). Science, 150, 893–899.

  • Wach S, Schirmacher P, Protschka M and Blessing M . (2001). Oncogene, 20, 7761–7769.

  • Wozney JM . (1989). Prog. Growth Factor Res., 1, 267–280.

  • Yamashita H, ten Dijke P, Huylebroeck D, Sampath TK, Andries M, Smith JC, Heldin CH and Miyazono K . (1995). J. Cell Biol., 130, 217–226.

  • Zavadil J, Brezinova J, Svoboda P, Zemanova Z and Michalova K . (1997). Leukemia, 11, 1187–1192.

  • Zimmerman LB, Jesus-Escobar JM and Harland RM . (1996). Cell, 86, 599–606.

Download references

Acknowledgements

We thank Hanne Hella, Berit F Stordal and Siv H Moen for excellent technical assistance. This study was supported by grants from The Norwegian Cancer Society, The Cancer Fund of St Olav's Hospital and The Norwegian Research Council.

Author information

Authors and Affiliations

  1. Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, MTFS, Trondheim, N-7489, Norway

    Torstein Baade Ro, Randi Utne Holt, Anne-Tove Brenne, Anders Waage, Anders Sundan & Magne Borset

  2. Department of Hematology, St Olav's Hospital, Trondheim, 7005, Norway

    Henrik Hjorth-Hansen & Oyvind Hjertner

Authors
  1. Torstein Baade Ro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Randi Utne Holt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anne-Tove Brenne
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Henrik Hjorth-Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anders Waage
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Oyvind Hjertner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Anders Sundan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Magne Borset
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Torstein Baade Ro.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baade Ro, T., Utne Holt, R., Brenne, AT. et al. Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells. Oncogene 23, 3024–3032 (2004). https://doi.org/10.1038/sj.onc.1207386

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207386

Keywords

Search

Advanced search

Quick links